Replimune - About the company
Replimune is a public company based in Oxford (United Kingdom), founded in 2015 by Philip Astley-Sparke, Colin Love and Robert Coffin. It operates as a Developer of oncolytic immunotherapies. Replimune has raised $87M in funding from Foresite Capital. The company has 3358 active competitors, including 1128 funded and 784 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of oncolytic immunotherapies. It is developing its pipeline intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. It is currently developing its programs and is planning to progress them rapidly through clinical trials and to combine these with checkpoint blockade at an early stage of clinical development.
- Website
- www.replimune.com/
- Social
- Email ID
- *****@replimune.com
- Registered Address
- Woburn, Massachusetts
Key Metrics
Founded Year
2015
Location
Oxford, United Kingdom
Stage
Public
Total Funding
$87M in 3 rounds
Latest Funding Round
Investors
Ranked
33rd among 3358 active competitors
Employee Count
341 as on Sep 30, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Replimune
Replimune is associated with 3 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
REPLIMUNE GROUP, INC. CIN: 1737953 , United States, Active | Jul 04, 2017 | - | - | - |
REPLIMUNE INC CIN: 474303094 , United States, Active | Dec 26, 999 | - | 322 (As on Dec 31, 2024) | - |
Replimune Limited CIN: 09496393 , United Kingdom, Active | Mar 17, 2015 | - | 152 (As on Mar 31, 2021) |
Replimune's IPO details
Replimune got listed on Jun 20, 2018.
Click here to take a look at Replimune's IPO in detail
Sign up to download Replimune's company profile
Replimune's funding and investors
Replimune has raised a total funding of $87M over 3 rounds. Its first funding round was on Apr 01, 2015. Its latest funding round was a Series B round on Sep 07, 2017 for $*****. 7 investors participated in its latest round. Replimune has 9 institutional investors.
Here is the list of recent funding rounds of Replimune:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 07, 2017 | 9678345 | Series B | 5570670 | 2617367 | 5015788 | 2131296 |
Sep 24, 2015 | 1297482 | Series A | 8409971 | 7239721 | 7392176 | |
Apr 01, 2015 | 9767624 | Seed | 9505859 | 7312746 | 9264348 | 1781554 |
Access funding benchmarks and valuations. Sign up today!View details of Replimune's funding rounds and investors
Replimune's founders and board of directors
Founder? Claim ProfileThe founders of Replimune are Philip Astley-Sparke, Colin Love and Robert Coffin. Philip Astley-Sparke is the CEO of Replimune.
Here are the details of Replimune's key team members:
- Philip Astley-Sparke: Co-Founder, CEO & Executive Chairman of Replimune. They serve on the board of 1 company.Contact Info: 1 email address
- Colin Love: Co-Founder & COO of Replimune. Contact Info: 1 email address
- Robert Coffin: Co-Founder & CEO of Replimune. Contact Info: 1 email address
View details of Replimune's Founder profiles and Board Members
Replimune's employee count trend
Replimune has 341 employees as of Sep 26. Here is Replimune's employee count trend over the years:
Uncover Replimune's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Replimune's Competitors and alternates
Top competitors of Replimune include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Replimune, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
33rd | Replimune 2015, Oxford (United Kingdom), Public | Developer of oncolytic immunotherapies | $87M | 68/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Replimune's competitors? Click here to see the top ones
Replimune's Investments and acquisitions
Replimune has made no investments or acquisitions yet.
Reports related to Replimune
Here is the latest report on Replimune's sector:
News related to Replimune
Filter this listMedia has covered Replimune for a total of 38 events in the last 1 year, 9 of them have been about company updates and 1 about people movement.
•
•
Replimune Group, Inc. Securities Class Action Lawsuit - Lead Plaintiff Deadline October 5, 2026GlobeNewswire•Sep 29, 2026•Replimune, Pomerantz, Bronstein, Gewirtz & Grossman
•
Replimune Approval: Localized Cancer Drugs Could Redefine Care, Experts SayBioSpace•Sep 21, 2026•Replimune
•
Securities Lawsuit Alert: ARS Pharmaceuticals, Inc. (SPRY) - Contact Levi & Korsinsky Before October 5, 2026Access Newswire•Sep 16, 2026•Levi & Korsinsky, ARS Pharmaceuticals, Atom, Replimune and 1 other
•
Pomerantz LLP Issues Important Reminder to Shareholders in Replimune Group, Inc. of Class Action Lawsuit – REPLAccess Newswire•Sep 13, 2026•Pomerantz, Replimune, Levi & Korsinsky
•
Bragar Eagel & Squire, P.C. Announces Class Action Lawsuit Against Replimune Group Inc.GlobeNewswire•Sep 11, 2026•Bragar Eagel & Squire, Replimune, Levi & Korsinsky, Robbins and 1 other
•
FDA Director Overrules Reviewers for Replimune's Melanoma Drug Tudriqev Accelerated ApprovalBioSpace•Sep 03, 2026•Replimune
•
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Stock Screener•Aug 20, 2026•Replimune
•
Replimune Group Inc. Lawsuit: Shareholders Reminded of Lead Plaintiff DeadlinePR Newswire•Aug 18, 2026•Securitiesclasslaw, Replimune, Bragar Eagel & Squire, Pomerantz and 3 others
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Replimune
Explore our recently published companies
- STAT4DECISION - France based, 2015 founded, Unfunded company
- Sabbagh - Unfunded company
- Vegas Builds - San Francisco based, 2015 founded, Unfunded company
- Observatorio 1987 - Argentina based, 2018 founded, Unfunded company
- LEVION Technologies - Austria based, 2014 founded, Unfunded company
- Paws and Claws Pet Sitter - Loveland based, Unfunded company
